...Business Strategy of Sandoz Bangladesh Term Paper on Business Strategy of Sandoz Bangladesh Submitted to Professor A K M Saiful Majid Course Instructor, Business Strategy (W650) Submitted by M Nakibur Rahman, Batch: 43D, Roll# 55 Wazedur Rahman, Batch: 46D, Roll# 143 Institute of Business Administration University of Dhaka 13 June 2013 Dr. A K M Saiful Majid Professor Institute of Business Administration University of Dhaka Dear Sir: We are pleased to submit our term paper on “Business Strategy of Sandoz Bangladesh” as per your kind guidance and instructions to fulfill the course requirements. Working for the paper had been of great learning experience for us. This project gave us the opportunity to analyze a real life sector that we could relate with the theoretical issues studied in the Business Strategy course. We are open to your queries and feedback regarding this report. Yours truly, Mohammad Nakibur Rahman Roll: 55, Batch: 43D Wazedur Rahman Roll: 143, Batch: 46D i Table of Contents Executive Summary ....................................................................... iii 1. Introduction ............................................................................. 1 1.1 1.2 Objective ................................................................................................................................. 1 Scope .............................................................................................................
Words: 3508 - Pages: 15
...The sector overview and Major players The Indian Pharmaceutical industry is highly fragmented with about 24,000 players (around 330 in the organised sector). The top ten companies make up for more than a third of the market. The Indian pharma industry (IPM) grew by 16% YoY in 2012 to ` 629 bn. It accounts for about 1.4% of the world's pharma industry in value terms and 10% in volume terms. Besides the domestic market, Indian pharma companies also have a large chunk of their revenues coming from exports. While some are focusing on the generics market in the US, Europe and semi-regulated markets, others are focusing on custom manufacturing for innovator companies. Biopharmaceuticals is also increasingly becoming an area of interest given the complexity in manufacture and limited competition. The drug price control order (DPCO) continues to be a menace for the industry. There are three tiers of regulations – on bulk drugs, on formulations and on overall profitability. This has made the profitability of the sector susceptible to the whims and fancies of the pricing authority. In connotation, with pricing policy of 354 drugs, NLEM (National list of essential medicines) was released, which covered the list of the drugs which the authority intends to put under price control. The policy has been stiffly opposed by the pharmaceutical industry. Introduction of GDUFA (Generic drug user fee Act) in US. As per this act, the generic companies are required to pay user fees to USFDA, for...
Words: 1721 - Pages: 7
...Term Paper Report On Competitive Marketing Policies & Strategies Of Pharmaceutical Products in Bangladesh Submitted to Mr. Abdus Samad Chowdhury Senior Management Councilor Bangladesh Institute of Management Submitted By MD. MAHAFUZUR RAHMAN ID: 14MM028 Post Graduate Diploma In Marketing Management Date of Submission 21-12- 2014. Bangladesh Institute of Management Department of Marketing Management Letter of Transmittal December 21, 2014 Mr. Abdus Samad Chowdhury Bangladesh Institute of Management Subject: Request to accept my term paper report on competitive marketing policies & strategies of Pharmaceutical Products in Bangladesh. Dear Sir, I have given a topic on “Competitive Marketing Policies & Strategies of Pharmaceutical Products in Bangladesh” for writing a term paper for presentation, collection of primary data and secondary data. To do so, we sought the relevant information from books, newspaper and websites. We also went to many respondents who are closely related this entire process. I tried to collect all possible information and make this paper acceptable to all but there can be still existing mistake. So we like to request you to consider if any fault is found in this paper. Finally I would like to request you to accept our paper and permit us to present it before the panel of experts. Yours Sincerely Md. Mahafuzur Rahman Roll No : 14MM028 Post Graduate Diploma in Marketing Management. Bangladesh...
Words: 9861 - Pages: 40
...Indian Pharma Industry – an overview April 13, 2012 The demand for pharmaceutical products in India is significant and is driven by low drug penetration, rising middle-class & disposable income, increased government & private spending on healthcare infrastructure, increasing medical insurance penetration etc. The Indian pharmaceutical industry is growing at about 8 to 9 percent annually according to “A Brief Report Pharmaceutical Industry in India,” published in January 2011. The Pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are approximately 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). I. Current Scenario: India's pharmaceutical market grew at 15.7 per cent during December 2011. Globally, Indiaranks third in terms of manufacturing pharma products by volume. According to McKinsey, the Pharmaceutical Market is ranked 14th in the world. By 2015 it is expected to reach top 10 in the world beating Brazil, Mexico, South Korea and Turkey. More importantly, the incremental market growth of US$ 14billion over the next decade is likely to be the third largest among all markets. The US and China are expected to add US$ 200bn and US$ 23bn respectively. McKinsey & Company’s report, “India Pharma 2020:...
Words: 1969 - Pages: 8
...10 7) Conclusion page 11 Bibliography page 12 8) 1. Introduction This paper briefly examines the current state of the pharmaceutical industry, as well as the economic characteristics, performance, and the impact of the global recession. The industry is made up of several enterprises engaging in the research, development, manufacture and marketing of medicines, vaccines, medical devices, and nutritional products for humans and animals. Though, this multi-billion dollar industry includes large ethical drug multi-nationals (often referred to as Big Pharma), mid-sized specialty pharmaceutical companies, manufacturers of generics, small biotechnology and biopharmaceutical firms, and service companies, 1 for the purpose of this paper, the emphasis will be mainly on drug makers. 2. History/Overview of the Industry The pharmaceutical industry of today is a far cry from its humble beginnings in the nineteenth century of physicians mainly prescribing plant extracts to being technology intensive, dominated by a few large companies with significant research and development (R&D) budgets, and significant government oversight. Over the past five years, the industry has been characterized by mega-mergers and acquisitions, company reorganizations, regulatory reform, expiring patent protection, and the growth of generics. Figure 1. Big Pharma Top 10 for 2010 The United States is the largest...
Words: 2796 - Pages: 12
...UCB: Managing Information for Globalization and Innovation BML 106 STUDENT NUMBER: 1108282 BML 106 STUDENT NUMBER: 1108282 CONTENTS Page 2: Company Background Page 3: Question 1 Page 4: Question 1 Page 5: Question 1& 2 Page 6: Question 2 Page 7: Question 2 & 3 Page 8: Question 3 & 4 Page 9: Question 4 Page 10: Question 4 Page 11: References & Bibliography BACKGROUND OF UCB Formally as Union Chimique Belge when it began in 1928, UCB was one of the largest concerns in Belgium. Being associated with one of the oldest chemical factories in Belgium, UCB had grown by acquisition of other companies. The organisation was split into three different sectors; Chemicals, Films and Pharma with Pharma being the biggest market as they moved into two therapeutic fields; allergy and neurology. Priding itself in its flexibility and ability to adapt, UCB saw sectors such as Pharma’s sales growing by 20% with a profit margin of 28% adopting the philosophy of taking ‘speed of action’ when it came to developing new information systems across the entire organisation. The company was known for its practicality as it looked for ‘quick wins and identifiable value in everything that it did.’ 1. Use the case study to identify one example, either of a business process or of a decision making area that is supported by IT /IS within UCB. Describe your example (along with a technical diagram or specification) and evaluate the benefits and...
Words: 3188 - Pages: 13
...created the world’s second largest company and was one of the biggest and most successful merger of all time. The research paper tries to give us an insight into how everything changed for both the companies and the reason for merger, along with the advantages and disadvantages. The initial part of the paper talks about both the companies. Glaxo Wellcome and Smith Kline Beecham, both were well aware of the merger and acquisition scenario as both the companies were the result of well known mergers and acquisitions in the pharma industry. Glaxo took over Wellcome Foundation and SmithKline Beckman had merged with Beechman earlier on. The new match seems more equal: both Glaxo and SB are financially fit and scientifically energetic. Their bosses are friends. Analysts lauded the plan, and M&A specialists made drooling predictions of the consolidation the deal will provoke. In January 2000, Glaxo Wellcome and SmithKline Beecham announced their $76bn proposed merger and shareholders approved by 99 per cent majority of shareholders, which was expected to give the combined company a global market share of 7.3 per cent and an R&D budget of $4bn. Sir Richard Sykes became the non-executive chairman, while Jean Paul Garnier became the CEO of the GlaxoSmithKline under the new corporate governance structure. Theoretically it was a horizontal merger. The paper further discusses the reasons for the merger, one of them being cutting cost by eliminating staff and closing the odd factory...
Words: 500 - Pages: 2
...Definition of Strategy Definition of Strategy: Strategy is a method or plan by which long term objectives will be achieved. Long term objectives are the specific result that an organization seeks to achieve in pursuing its basic mission. Business strategies may involve geographic expansion, diversification, acquisition, product development, market penetration, retrenchment, divestiture, liquidation and joint ventures. Strategies are potential actions that require top management decision and large amount of farm’s resources. Additionally strategies affect an organization’s long term prosperity, typically for at least five years, and thus are future oriented. Strategies have multifunctional and multidivisional consequences and required consideration of both the external and internal factors facing the firm. Most Strategic Management Model There are several Strategic Models are available and used in different organizations but following are the most used strategic models: 1. PEST analysis 2. STEER Analysis 3. Five Forces Model 4. Strategic Group Map 5. SWOT analysis 6. Blue Ocean Strategies 7. Open innovation 8. McKinsey seven S model Company Detailed Profile including mission & vision and Organogram Company Detail Profile Square pharmaceutical is now the most leading company in Bangladesh since 1985 and is now on its way to becoming a high performance global player. Today it has achieved a state of mind among consumers...
Words: 5122 - Pages: 21
...ISSN: 2319-5894 Pharma Utility Volume 8, Issue 1- 2, 2014 Brief Report Indian Chemical Industry: A Potential Chemical Hub for Exploration at World Market Authors: Amrit B Karmarkar*1, Avinash D Deodhar1, Aditya A Holikar2 Affiliations: 1. Director, InClinition, Dombivli East, Mumbai Area, India 2. Research Associate, InClinition, Dombivli East, Mumbai Area, India Email: amrit@inclinition.com Cellular: +91-8898904115 Introduction of Chemical Industry Chemicals are the basic necessity of day to day life for creature to survive on earth. The chemicals whether being natural or synthetic they are helpful to each and every creature for the survival. Right from the food we eat, clothes we wear or the cars we drive all the things are significantly based on the chemicals which helps to enhance the quality of life through various new innovations. The use of chemicals is mentioned from the ancient time to the modern era. As the development on earth started from the ancient era to modern era for the survival and the enhancement of the chemicals, their forms and their uses changed. Development of synthetic chemicals took place by setting up the chemical factory in countries and then export and import of chemicals from country to country. As the modern era is concern, the chemical industry has acquired the special attention by Compound Annual Growth Rate (CAGR) at 5.9% for the revenue generation of $ 3,519 billion till year 2010. It is expected to grow up to 8.1% generating $ 5,185 billion...
Words: 1600 - Pages: 7
...Executive Summary After growing at a robust twenty plus percentage in 2010 and 2011, Bangladesh Pharmaceutical Industry experienced a slower growth in 2012. The market grew by 11.9% in value terms to reach at Tk. 94 billion (IMS: Q4 2012 report). Despite a slower growth in the market, Beximco Pharma managed to achieve desired growth and successfully improve its market share. The country continued to maintain 6% plus GDP growth rate in 2012 as well. The alarming depreciation of Taka against US Dollar that continued throughout 2011 till January 2012 has finally been restrained. Thanks to higher inward remittances, lower payment for import settlements, and moderate growth in export. The local currency appreciated by around 2.5% against US Dollar in 2012. This was somewhat a relief to the predicted risk of significant reduction of gross margin that started brewing in 2011 in the wake of deteriorating value of local currency against US Dollar, high rate of domestic inflation and increase in the interest rates. The liquidity shortage that prevailed throughout 2011 also eased up to some extent in 2012. However, the political crisis that started by end of 2012 centering the upcoming election poses some degree of uncertainty in the overall economic environment of the country and is seen as an impediment to the growth of business. The first quarter of 2013 has already been affected for such instability in the political environment and continues to remain as a risk factor. ...
Words: 5929 - Pages: 24
...Limiting Big Pharma’s Power: Eric Sills Executive Summary This policy brief examines the power dynamic of the pharmaceutical industry with regards to its influence in Washington. By exerting so much influence in the arena where the drug laws are drawn up, discussed, and passed, the pharmaceutical industry, also known as BIG Pharma due to their scope, size, and influence, has negatively affected the consumer in its market, namely the medical patient. The drug industry has done this through lobbying in Washington to keep laws relating to the pharmaceutical market favorable for the drug companies themselves. This brief examines three possible solutions to this problem: lobbying spending and lobbyist limits for pharmaceutical companies, a ban on direct advertisements by pharmaceutical companies, and more transparency and screening before prescribing prescription pain killers. In this analysis, the first alternative represents the best solution to this problem as it has the highest overall potential for benefit and less total cost than the other two possible solutions. Introduction/Background This policy brief examines the pharmaceutical industry and how it has come to gain too much power not only with regards to market power in its industry but also with regards to their influence in Washington. By having this much power, drug companies have negatively affected medical consumers/patients through continued increased prices and a steady decline in innovation. Steps...
Words: 3199 - Pages: 13
...DOCUMENT TYPE DOC NO. REVISION Quality Management Policy TITLE ISSUED BY QMP-001 EFFECTIVE DATE 1.0 PAGE Q Pharma Quality System Manual rJ Boatman 16 Feb 2007 1 of 32 SUPERCEDES CSSC QSM-001 iPT QSM-001 QUALITY MANAGEMENT POLICY QUALITY SYSTEM MANUAL QMP-001 Rev. 1.0 Prepared by Date (Signed) Jeff Boatman, Director of Quality Reviewed by 01 Feb 2007 Date (Signed) Alexis Stroud, Compliance Manager Reviewed by 07 Feb 2007 Date (Signed) Raymond Roggero, iPT Business Unit Manager Reviewed by 2/7/07 Date (Signed) Robert Lorence, CSSC Business Unit Manager Approved by 9 Feb 2007 Date (Signed) Patrick Den Boer, President and CEO 16 Feb 2007 ©2007 Q Pharma Incorporated. Unauthorized reproduction or distribution prohibited. CONTROLLED DOCUMENT • VERIFY LATEST REVISION • PRINTED COPY IS UNCONTROLLED IF NOT STAMPED IN RED DOCUMENT TYPE DOC. NO. REVISION Quality Management Policy TITLE QMP-001 1.0 PAGE Quality System Manual TABLE OF CONTENTS 0. Page 2 of 32 1. 2. 3. 4. 5. 6. INTRODUCTION .........................................................................................................................4 0.1 General...............................................................................................................................4 0.2 Process Approach ................................................................................................................
Words: 10681 - Pages: 43
...www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers...
Words: 13197 - Pages: 53
...licensing, outsourcing and partnerships will be covered. The student will gain an understanding of R&D strategy and the relationship between R&D and overall organizational success. Pedagogy The course will employ lectures notes, assigned readings, case analyses, individual homework assignments, and a final project. Each student will analyze three cases from the Harvard Business Review involving pharmaceutical companies. The final project will be a written paper touching on some aspect of managing pharmaceutical research and development. Relationship of Course to the Rest of the Curriculum The pharma value chain comprises all of the functional business elements from drug discovery through commercialization, and includes critical supporting functions, such as supply chain logistics and regulatory and compliance. IT is an enabler at the strategic and operational levels for all elements of the functional pharma value chain. Hence there is a strong synergy between the business functions comprising the pharma value chain and the IT strategic/operational platform enabling those functions. It leads to a common body of knowledge encompassing both the business and IT domains that is required for optimal planning and execution of the...
Words: 2063 - Pages: 9
...large business organization. Specially, the multi-national nonprofit or profit seeking organizations such as Coca cola, IBM etc. are often termed as the corporation. Social responsibility: Social responsibility is an ethical theory that an entity, be it an organization or , has an obligation to act to benefit society at large. Social responsibility is a duty every individual has to perform so as to maintain a balance between the economy and the ecosystems. Corporate social responsibility: Corporate initiative to assess and take responsibility for the company’s effects on the environment and impact on social welfare. The term generally applies to Company efforts that go beyond what may be required by regulators or environment protection groups. Corporate social responsibility may also be referred to as “corporate citizenship” and can involve incurring short-term costs that do not provide an immediate financial benefit to the company, but instead promote positive social and environmental changes and also a change in the community’s attitude toward the company. Companies have a lot of power in the community and in the national economy. They control a lot of assets, and may have billions in cash at their disposal for socially conscious investments and programs. Some companies may engage in "green washing", or feigning interest in corporate responsibility, but many large corporations are devoting real time and money to environmental sustainability programs, alternative energy/cleantech...
Words: 3789 - Pages: 16
